



## Shareholder approval VanEck Bionic Engineering UCITS ETF: Investment Objective and Policy Amendment

VanEck wishes to announce that the shareholders of the VanEck Bionic Engineering UCITS ETF (the “Fund”) approved the amendment of the investment objective and policy of the Fund at the Extraordinary General Meeting held on 14 August 2025.

The investment objective and policy of the Fund, as detailed in Section 1 of the Circular dated 21 July 2025, will be amended to reflect an adjustment to the index methodology to apply an additional screen for companies involved in the “medical robotics” industry when selecting the constituents of the index, which becomes effective on or around 19 September 2025 (the “Effective Date”).

As a result of the passing of the resolutions, to better align the name of the Fund with its revised investment objective and policy, the Fund will be re-named as of the Effective Date, as set out below:

Existing Fund name	Proposed Fund name
VanEck Bionic Engineering UCITS ETF	VanEck Medical Robotics and Bionic Engineering UCITS ETF

For further details on the current investment objective of the Fund, as well as the related amendments, please refer to following documentation published on [www.vaneck.com](http://www.vaneck.com):

- **Shareholder circular**
- **FAQ**

Yours faithfully,

**VanEck UCITS ETFs plc**